Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Front Biosci (Landmark Ed). 2012 Jan 1;17(2):635-55. doi: 10.2741/3949.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only truly effective curative treatment for refractory hematological malignancies. Unfortunately, relapse and transplant rejection continue to be of major concern. In order to enhance the effectiveness of the HSCT, various strategies have been explored to amplify the graft versus leukemia (GvL) effect. Cancer vaccines have emerged in recent years as a promising strategy for the immunotherapeutic treatment of cancer. Evidence shows that they are most likely to have the greatest effect in the setting of minimal residual disease and as adjuvant agents. With this in mind, researchers have begun to explore the use of cancer vaccines in conjunction with HSCT, with exciting results. There has also been recent work examining the effect of novel adjuvants or blockers of negative immune regulation to augment the effect of cancer vaccines in both the transplant and non-transplant settings. The addition of these agents may prove.
异基因造血干细胞移植（HSCT）仍然是治疗难治性血液系统恶性肿瘤的唯一真正有效的根治性治疗方法。不幸的是，复发和移植物排斥仍是主要关注点。为了提高 HSCT 的效果，已经探索了各种策略来增强移植物抗白血病（GvL）效应。近年来，癌症疫苗作为癌症免疫治疗的一种有前途的策略出现了。有证据表明，它们在微小残留疾病和辅助剂的情况下最有可能产生最大的效果。考虑到这一点，研究人员已经开始探索将癌症疫苗与 HSCT 联合使用，取得了令人兴奋的结果。最近也有研究探讨了新型佐剂或负性免疫调节抑制剂的作用，以增强移植和非移植环境中癌症疫苗的效果。添加这些药物可能会被证明是。
